Kimia biosciences Limited has announced a significant leadership change with the resignation of its Chief Financial Officer (CFO) Mr. Naveen Sharma, effective February 2, 2026. The pharmaceutical company communicated this development to BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

Mr. Naveen Sharma tendered his resignation from the position of CFO and key managerial personnel on February 2, 2026, citing personal reasons for his departure. He will be relieved from his responsibilities with the close of business hours on the same date.

Regulatory Compliance

The company has fulfilled all mandatory disclosure requirements under SEBI regulations. Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signed the official intimation letter, ensuring compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The resignation letter was formally submitted through email communication from Mr. Sharma to the company management, requesting proper filing with the Registrar of Companies (ROC) and appropriate intimation to stock exchanges as per regulatory framework.

Company Information

Kimia Biosciences Limited operates from its registered office at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana, with corporate office located in New Delhi. The company trades on BSE under scrip code 530313 with the symbol KIMIABL.

Documentation

All required annexures and supporting documents have been submitted to the stock exchange, including detailed particulars of the cessation as mandated by SEBI listing regulations. The company has maintained transparency in its disclosure process throughout this leadership transition.

Kimia Biosciences Limited has announced the appointment of Mr. Naveen Sharma as Chief Financial Officer, effective January 7, 2026. This appointment follows the recent resignation of former CFO Mr. Pradip Kumar Sharma, who stepped down on January 6, 2026, citing personal reasons. The pharmaceutical company informed BSE Limited about both key managerial personnel changes under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Leadership Transition Details

The Board of Directors approved Mr. Naveen Sharma's appointment during their meeting held on January 7, 2026, which commenced at 14:30 PM and concluded at 15:00 PM. This swift appointment demonstrates the company's commitment to maintaining continuity in its financial leadership. The transition occurred just one day after the previous CFO's departure, ensuring minimal disruption to the company's operations.

New CFO Profile and Experience

Mr. Naveen Sharma brings extensive expertise to his new role as a Chartered Accountant with over 18 years of experience in finance, accounting, governance, and strategic leadership. His professional background spans across multiple sectors including financial services, EPC, manufacturing, and banking. He possesses comprehensive expertise in financial controlling, business planning, commercial finance, ERP implementation, digital transformation, governance, and regulatory compliance.

Regulatory Compliance and Documentation

The company has fulfilled its obligations under SEBI regulations by submitting the required documentation to BSE Limited for both the resignation and appointment. Company Secretary and Compliance Officer Pallavi Garg (Membership No.: A69848) signed the official intimation documents on January 7, 2026. The filing includes all details mandated under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Information

Kimia Biosciences Limited operates in the pharmaceutical sector with its registered office and works located at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. The company maintains its corporate office at Aggarwal Millennium Tower-II, Netaji Subhash Place, Pitampura, New Delhi. The company trades on BSE under scrip code 530313 with the symbol KIMIABL. Additional information regarding these appointments is available on the company's website at www.kimiabiosciences.com .